Fujirebio Reports the Regulatory Submission of Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio IVD Test to the US FDA for Alzheimer's Disease
Shots:
- Fujirebio has submitted application for Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio IVD blood test to the US FDA for diagnosing Alzheimer’s disease (AD)
- The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test, designated as a breakthrough device, measures pTau 217 and β-Amyloid 1-42 concentrations in plasma and converts it into the numerical ration of concentrations to diagnose amyloid pathology linked to Alzheimer's disease
- The test works on Fujirebio’s automated Lumipulse G1200 system. It complements the FDA-approved Lumipulse G β-Amyloid Ratio (1-42/1-40) test for CSF
Ref: Fujirebio | Image: Fujirebio
Related News: Eli Lilly's Kisunla (Donanemab-azbt) Receives the MHLW’s Approval for Treating Early Symptomatic Alzheimer's Disease (AD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
